1. Home
  2. LCTX vs SWBI Comparison

LCTX vs SWBI Comparison

Compare LCTX & SWBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo Smith & Wesson Brands Inc.

SWBI

Smith & Wesson Brands Inc.

HOLD

Current Price

$10.76

Market Cap

491.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
SWBI
Founded
1990
1852
Country
United States
United States
Employees
N/A
1416
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Ordnance And Accessories
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
491.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LCTX
SWBI
Price
$1.71
$10.76
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$4.25
$11.00
AVG Volume (30 Days)
1.2M
506.9K
Earning Date
11-06-2025
03-05-2026
Dividend Yield
N/A
4.71%
EPS Growth
N/A
N/A
EPS
N/A
0.21
Revenue
$10,816,000.00
$466,396,000.00
Revenue This Year
$6.32
$2.62
Revenue Next Year
$124.49
$3.23
P/E Ratio
N/A
$52.80
Revenue Growth
24.05
N/A
52 Week Low
$0.37
$7.73
52 Week High
$2.09
$11.50

Technical Indicators

Market Signals
Indicator
LCTX
SWBI
Relative Strength Index (RSI) 50.38 60.97
Support Level $1.64 $10.47
Resistance Level $1.79 $11.08
Average True Range (ATR) 0.09 0.26
MACD 0.00 0.04
Stochastic Oscillator 51.92 76.33

Price Performance

Historical Comparison
LCTX
SWBI

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

Share on Social Networks: